# A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

> **NCT04761744** · PHASE2 · UNKNOWN · sponsor: **Korean Cancer Study Group** · enrollment: 48 (estimated)

## Conditions studied

- DDR Gene Mutation
- Metastatic Solid Tumor

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04761744
- **Lead sponsor:** Korean Cancer Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-14
- **Primary completion:** 2021-03
- **Final completion:** 2021-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04761744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04761744, "A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04761744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*